 BOULDER, Colo.--BUSINESS WIRE--- BDSX patientsfirst--Biodesix, Inc. Nasdaq: BDSX, a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer IASLC World Conference on Lung Cancer WCLC. The Role of Serum Proteomic Signature in Predicting Survival by PD-L1 Status in Patients with Non-Small Cell Lung Cancer R 